.

Vanderbilt Department of Neurology

Clinical Trials in Multiple Sclerosis

The following studies are being conducted by the Division of Neuroimmunology:

A Four-arm Randomized, Double-blind, Placebo-controlled, Multicentre Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of Three Doses of Atacicept Monotherapy in Subjects with Relapsing Multiple Sclerosis (RMS) Over a 36 Weeks Treatment Course (Protocol 28063)

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis

Longitudinal analysis of immunoglobulin changes in the CSF of patients who present with clinically isolated syndrome or Relapsing Remitting Multiple Sclerosis

A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif® ) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy

A Randomized, Multicenter, Placebo-controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Regulation of Expression and Function of P53 by Beta Interferon

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Rebif New Formulation in Multiple Sclerosis Subjects with Active Disease

TYGRIS: TYSABRI Global Observational Program in Safety

Regulation of p53 Signaling Defects in MS

The Open-label, Compassionate, Pilot Use of Antibiotics for Patients with Progressive MS

Cerebrospinal Fluid Analysis Utilizing Recent Advances in Proteomic Research

National Institute of Neurological Disorders and Stroke Biomarkers in Multiple Sclerosis Study

A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis (CombiRx-Phase III)

Regulation of p53 Expression by B-Interferon

Biogen Idec study no. 105MS301 entitled “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis"

For questions regarding clinical protocols:

Jean Simmons, R.N. - 615-322-4322

Jennifer Scott, R.N. - 615-322-4085

Cathleen Moore, R.N. - 615-322-4015

This page was last updated August 10, 2011 and is maintained by